135 related articles for article (PubMed ID: 27878356)
41. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.
Feun L; Modiano M; Lee K; Mao J; Marini A; Savaraj N; Plezia P; Almassian B; Colacino E; Fischer J; MacDonald S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):223-9. PubMed ID: 12203104
[TBL] [Abstract][Full Text] [Related]
42. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
[TBL] [Abstract][Full Text] [Related]
44. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
45. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
[TBL] [Abstract][Full Text] [Related]
46. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
47. A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Horiuchi Y; Kumada S; Haruta J; Yamaguchi T; Sugihara M; Ina K; Kusugami K; Goto S
Anticancer Res; 2005; 25(2B):1297-301. PubMed ID: 15865081
[TBL] [Abstract][Full Text] [Related]
48. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
[TBL] [Abstract][Full Text] [Related]
49. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
[TBL] [Abstract][Full Text] [Related]
50. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
51. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
[TBL] [Abstract][Full Text] [Related]
52. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
53. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Shin DM; Munden R; Fox N; Huyghe MR; Kean Y; Reich SD; Hong WK
J Clin Oncol; 2001 May; 19(10):2626-37. PubMed ID: 11352954
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
55. Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
Shimoyama S; Imamura K; Hiki N; Yamaguchi H; Mafune K; Kaminishi M
Int J Clin Oncol; 2005 Aug; 10(4):251-5. PubMed ID: 16136370
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.
Masters GA; Haraf DJ; Hoffman PC; Drinkard LC; Krauss SA; Ferguson MK; Olak J; Samuels BL; Golomb HM; Vokes EE
J Clin Oncol; 1998 Jun; 16(6):2157-63. PubMed ID: 9626216
[TBL] [Abstract][Full Text] [Related]
57. Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix.
Prasad E; Viswanathan PN; Rangad VF; Pavamani S; Ram TS
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):488-93. PubMed ID: 19386478
[TBL] [Abstract][Full Text] [Related]
58. Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.
Kunos CA; Ivy SP
Front Oncol; 2018; 8():149. PubMed ID: 29868473
[TBL] [Abstract][Full Text] [Related]
59. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.
Dickson MA; Carvajal RD; Merrill AH; Gonen M; Cane LM; Schwartz GK
Clin Cancer Res; 2011 Apr; 17(8):2484-92. PubMed ID: 21257722
[TBL] [Abstract][Full Text] [Related]
60. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
